Long-term efficacy and safety of paliperidone palmitate once-monthly in Chinese patients with recent-onset schizophrenia
Tianmei Si,1,2 Jianmin Zhuo,3 Yu Feng,4 Huafei Lu,5 Di Hong,5 Lili Zhang51National Clinical Research Center for Mental Disorders & The Key Laboratory of Mental Health, Ministry of Health (Peking University), Beijing, People’s Republic of China; 2Peking University Institute of Menta...
Guardado en:
| Autores principales: | , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2019
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/6b9f26ff9faa4520b50ab464bab6b85b |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: | Tianmei Si,1,2 Jianmin Zhuo,3 Yu Feng,4 Huafei Lu,5 Di Hong,5 Lili Zhang51National Clinical Research Center for Mental Disorders & The Key Laboratory of Mental Health, Ministry of Health (Peking University), Beijing, People’s Republic of China; 2Peking University Institute of Mental Health/The Sixth Hospital, Beijing, People’s Republic of China; 3Janssen (China) Research & Development Center, Johnson & Johnson (China) Investment Ltd., Shanghai, People’s Republic of China; 4Department of Neuroscience, Janssen Pharmaceutical Companies of Johnson and Johnson, Singapore; 5Medical Affairs, Xi’an Janssen Pharmaceuticals, Beijing, People’s Republic of ChinaBackground: The subgroup analysis of a primary study (NCT01051531) evaluated the effect of long-term paliperidone palmitate once-monthly (PP1M) therapy in Chinese patients with recent-onset schizophrenia responding unsatisfactorily to previous oral antipsychotics.Patients and methods: This 18-month, open-label study consisted of 3 phases – screening (7 days), treatment (18 months) and end-of-study/withdrawal visit. All enrolled patients (18–50 years) received PP1M: 150 mg eq. (day 1), 100 mg eq. (day 8) followed by a once-monthly flexible dose (50, 75, 100 or 150 mg eq.). Efficacy and safety were assessed.Results: Among the 118 enrolled Chinese patients, 68 completed the treatment (mean age: 25.6 years; male: 54.7%). A clinically meaningful change from baseline to day 548 was observed in Positive and Negative Syndrome scale (primary endpoint, mean [SD]: −15.3 [20.76]), Personal and Social Performance scale (15.9 [19.65]), Clinician Global Impression-schizophrenia score (−1.2 [1.54]) and Medication Satisfaction Questionnaire score (0.9 [1.73]). Commonly reported treatment-emergent adverse events (TEAEs) included insomnia (13.9%), injection-site pain (13.9%), upper respiratory tract infection (13.0%), restlessness (13.0%) and akathisia (13.0%). Serious TEAEs were reported in 9.3% patients with schizophrenia being most common (6.5%) and one death (suicide) was observed.Conclusion: Efficacy of PP1M corroborate findings from earlier studies and no new safety concerns emerged in this Chinese subgroup of patients with schizophrenia.Keywords: Chinese patients, long-acting injectable, maintenance therapy, paliperidone palmitate once-monthly, schizophrenia |
|---|